{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:27:40Z","timestamp":1793291260545,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,11,26]],"date-time":"2016-11-26T00:00:00Z","timestamp":1480118400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s00259-016-3573-4","type":"journal-article","created":{"date-parts":[[2016,11,26]],"date-time":"2016-11-26T11:07:13Z","timestamp":1480158433000},"page":"678-688","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":542,"title":["F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients"],"prefix":"10.1007","volume":"44","author":[{"given":"Frederik L.","family":"Giesel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cardinale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Radtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vinsensia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Lehnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Tolstov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Grabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Duensing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. C.","family":"Neels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Mier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Haberkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kopka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kratochwil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,26]]},"reference":[{"issue":"2","key":"3573_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","volume":"42","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197\u2013209. doi: 10.1007\/s00259-014-2949-6 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"3573_CR2","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2967\/jnumed.115.154153","volume":"56","author":"M Eiber","year":"2015","unstructured":"Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56(5):668\u201374. doi: 10.2967\/jnumed.115.154153 .","journal-title":"J Nucl Med"},{"issue":"8","key":"3573_CR3","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","volume":"56","author":"JJ Morigi","year":"2015","unstructured":"Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective comparison of 18F-Fluoromethylcholine versus 68Ga-PSMA PET\/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56(8):1185\u201390. doi: 10.2967\/jnumed.115.160382 .","journal-title":"J Nucl Med"},{"issue":"1","key":"3573_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","volume":"41","author":"A Afshar-Oromieh","year":"2014","unstructured":"Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11\u201320. doi: 10.1007\/s00259-013-2525-5 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"3573_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13014-016-0646-2","volume":"11","author":"S Dewes","year":"2016","unstructured":"Dewes S, Schiller K, Sauter K, Eiber M, Maurer T, Schwaiger M, et al. Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study. Radiat Oncol. 2016;11(1):73. doi: 10.1186\/s13014-016-0646-2 .","journal-title":"Radiat Oncol"},{"issue":"1","key":"3573_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s00259-015-3188-1","volume":"43","author":"F Sterzing","year":"2016","unstructured":"Sterzing F, Kratochwil C, Fiedler H, Katayama S, Habl G, Kopka K, et al. (68)Ga-PSMA-11 PET\/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2016;43(1):34\u201341. doi: 10.1007\/s00259-015-3188-1 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3573_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.12.053","author":"M Eiber","year":"2016","unstructured":"Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, et al. Simultaneous 68Ga-PSMA HBED-CC PET\/MRI improves the localization of primary prostate cancer. Eur Urol. 2016. doi: 10.1016\/j.eururo.2015.12.053 .","journal-title":"Eur Urol"},{"key":"3573_CR8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.169243","author":"K Rahbar","year":"2016","unstructured":"Rahbar K, Weckesser M, Huss S, Semjonow A, Breyholz H, Schrader A, et al. Correlation of intraprostatic tumor extent with 68-Ga-PSMA distribution in patients with prostate cancer. J Nucl Med. 2016. doi: 10.2967\/jnumed.115.169243 .","journal-title":"J Nucl Med"},{"issue":"8","key":"3573_CR9","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1007\/s00259-016-3346-0","volume":"43","author":"FL Giesel","year":"2016","unstructured":"Giesel FL, Sterzing F, Schlemmer HP, Holland-Letz T, Mier W, Rius M, et al. Intra-individual comparison of 68Ga-PSMA11-PET\/CT and multi-parametric MR for imaging of primary prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43(8):1400\u20136. doi: 10.1007\/s00259-016-3346-0 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3573_CR10","doi-asserted-by":"crossref","unstructured":"Fendler WP, Schmidt DF, Wenter V, Thierfelder KM, Zach C, Stief C, et al. 68Ga-PSMA-HBED-CC PET\/CT detects location and extent of primary prostate cancer. J Nucl Med. 2016.","DOI":"10.2967\/jnumed.116.172627"},{"issue":"11","key":"3573_CR11","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.2967\/jnumed.114.140426","volume":"55","author":"S Vallabhajosula","year":"2014","unstructured":"Vallabhajosula S, Nikolopoulou A, Babich JW, Osborne JR, Tagawa ST, Lipai I, et al. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer. J Nucl Med. 2014;55(11):1791\u20138. doi: 10.2967\/jnumed.114.140426 .","journal-title":"J Nucl Med"},{"key":"3573_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.apradiso.2012.06.034","volume":"76","author":"A Sanchez-Crespo","year":"2013","unstructured":"Sanchez-Crespo A. Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot. 2013;76:55\u201362. doi: 10.1016\/j.apradiso.2012.06.034 .","journal-title":"Appl Radiat Isot"},{"issue":"12","key":"3573_CR13","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.2967\/jnumed.112.104661","volume":"53","author":"SY Cho","year":"2012","unstructured":"Cho SY, Gage KL, Mease RC, et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012;53(12):1883\u201391. doi: 10.2967\/jnumed.112.104661 .","journal-title":"J Nucl Med"},{"issue":"4","key":"3573_CR14","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","volume":"17","author":"Z Szabo","year":"2015","unstructured":"Szabo Z, Mena E, Rowe SP, et al. Initial evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17(4):565\u201374. doi: 10.1007\/s11307-015-0850-8 .","journal-title":"Mol Imaging Biol"},{"issue":"8","key":"3573_CR15","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Giesel FL, Stefanova M, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617. J Nucl Med. 2016;57(8):1170\u20136. doi: 10.2967\/jnumed.115.171397 .","journal-title":"J Nucl Med"},{"issue":"11","key":"3573_CR16","doi-asserted-by":"crossref","first-page":"12477","DOI":"10.18632\/oncotarget.7245","volume":"7","author":"H Ahmadzadehfar","year":"2016","unstructured":"Ahmadzadehfar H, Eppard E, K\u00fcrpig S, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7(11):12477\u201388.","journal-title":"Oncotarget"},{"key":"3573_CR17","doi-asserted-by":"crossref","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, et al. 225Ac-PSMA-617 for PSMA targeting alpha-radiation therapy of patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2016.","DOI":"10.2967\/jnumed.116.178673"},{"issue":"10","key":"3573_CR18","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s00259-016-3447-9","volume":"43","author":"FL Giesel","year":"2016","unstructured":"Giesel FL, Cardinale J, Sch\u00e4fer M, et al. 18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. Eur J Nucl Med Mol Imaging. 2016;43(10):1929\u201330. doi: 10.1007\/s00259-016-3447-9 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3573_CR19","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1021\/acs.jmedchem.5b01210","volume":"59","author":"M Bene\u0161ov\u00e1","year":"2015","unstructured":"Bene\u0161ov\u00e1 M, Bauder-W\u00fcst U, Sch\u00e4fer M, et al. Linker modification strategies to control the Prostate-Specific Membrane Antigen (PSMA)-targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors. J Med Chem. 2015;59:1761\u201375.","journal-title":"J Med Chem"},{"key":"3573_CR20","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1021\/jm9015813","volume":"53","author":"DE Olberg","year":"2010","unstructured":"Olberg DE, Arukwe JM, Grace D, et al. One step radiosynthesis of 6-[18F]Fluoronicotinic Acid 2,3,5,6-Tetraflourophenyl Ester ([18F]-F-Py-TFP): a new prosthetic group for the efficient labeling of biomolecules with fluorine-18. J Med Chem. 2010;53:1732\u201340.","journal-title":"J Med Chem"},{"key":"3573_CR21","doi-asserted-by":"publisher","unstructured":"Cardinale J, Sch\u00e4fer M, Bene\u0161ov\u00e1 M, et al. Preclinical evaluation of 18F-PSMA-1007: a new PSMA-ligand for prostate cancer imaging. J Nucl Med. 2016. doi: 10.2967\/jnumed.116.181768 .","DOI":"10.2967\/jnumed.116.181768"},{"key":"3573_CR22","first-page":"1245","volume":"43","author":"S Shen","year":"2002","unstructured":"Shen S, Meredith RF, Duan J, Macey DJ, Khazaeli MB, Robert F, et al. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non\u2013marrow-targeting 90Y-antibody therapy. J Nucl Med. 2002;43:1245\u201353.","journal-title":"J Nucl Med"},{"key":"3573_CR23","first-page":"689","volume":"34","author":"G Sgouros","year":"1993","unstructured":"Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689\u201394.","journal-title":"J Nucl Med"},{"issue":"3","key":"3573_CR24","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/rpd\/nct337","volume":"162","author":"M Andersson","year":"2013","unstructured":"Andersson M, Johansson L, Minarik D, Mattsson S, Leide-Svegborn S. An internal radiation dosimetry computer program, IDAC2.0, for estimation of patient dose for radiopharmaceuticals. Radiat Prot Dosim. 2013;162(3):299\u2013305.","journal-title":"Radiat Prot Dosim"},{"issue":"6","key":"3573_CR25","first-page":"1023","volume":"46","author":"MG Stabin","year":"2005","unstructured":"Stabin MG, Sparks RB, Crowe E. OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46(6):1023\u20137.","journal-title":"J Nucl Med"},{"key":"3573_CR26","first-page":"149","volume":"41","author":"MG Stabin","year":"2000","unstructured":"Stabin MG, Konijnenberg M. Re-evaluation of absorbed fractions for photons and electrons in small spheres. J Nucl Med. 2000;41:149\u201360.","journal-title":"J Nucl Med"},{"key":"3573_CR27","doi-asserted-by":"crossref","unstructured":"ICRP: basic anatomical and physiological data for use in radiological protection reference values. ICRP Publication 89. Ann. ICRP. 2002; 32 (3\u20134): 1\u2013277.","DOI":"10.1016\/S0146-6453(03)00002-2"},{"key":"3573_CR28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/modpathol.2010.156","volume":"24","author":"TH Kwast van der","year":"2011","unstructured":"van der Kwast TH, Amin MB, Billis A, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Mod Pathol. 2011;24:16\u201325.","journal-title":"Mod Pathol"},{"issue":"4","key":"3573_CR29","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"A Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40(4):486\u201395. doi: 10.1007\/s00259-012-2298-2 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"3573_CR30","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","volume":"56","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Hetzheim H, Kratochwil C, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET\/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56(11):1697\u2013705. doi: 10.2967\/jnumed.115.161299 .","journal-title":"J Nucl Med"},{"key":"3573_CR31","doi-asserted-by":"crossref","unstructured":"Pfob CH, Ziegler S, Graner FP, K\u00f6hner M, Schachoff S, Blechert B, et al. Biodistribution and radiation dosimetry of 68Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2016.","DOI":"10.1007\/s00259-016-3424-3"},{"issue":"9","key":"3573_CR32","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s00259-016-3419-0","volume":"43","author":"A Afshar-Oromieh","year":"2016","unstructured":"Afshar-Oromieh A, Hetzheim H, K\u00fcbler W, Kratochwil C, Giesel FL, Hope TA, et al. Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging. 2016;43(9):1611\u201320. doi: 10.1007\/s00259-016-3419-0 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"3573_CR33","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.eururo.2015.06.010","volume":"69","author":"L Bud\u00e4us","year":"2016","unstructured":"Bud\u00e4us L, Leyh-Bannurah SR, Salomon G, et al. Initial experience of (68)Ga-PSMA PET\/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol. 2016;69(3):393\u20136. doi: 10.1016\/j.eururo.2015.06.010 .","journal-title":"Eur Urol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-016-3573-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-016-3573-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-016-3573-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T20:28:08Z","timestamp":1568579288000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-016-3573-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,26]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["3573"],"URL":"https:\/\/doi.org\/10.1007\/s00259-016-3573-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,26]]}}}